Prevalence of *Candida* blood stream infections among children in tertiary care hospital: detection of species and antifungal susceptibility

This article was published in the following Dove Press journal: Infection and Drug Resistance

Sahar Mohammed Khairat¹ Amal Mohammed Sayed¹ Mohammad Nabih² Noha Salah Soliman³ Y osra Mohammed Hassan³

¹Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt; ²Department of Pediatrics, Faculty of Medicine, Cairo University, Giza, Egypt; ³Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt

**Background:** Of all blood stream infections (BSI), candidaemia poses the greatest threat with a high fatality rate among children. There has been an increase in the number of reports of non-*C. albicans* species and antifungal resistance has progressively emerge.

**Aim:** The present study aimed to demonstrate the prevalence of candidaemia among children and to characterize the involved species and their susceptibility to antifungal agents.

**Methodology:** Microbes were isolated from blood samples and identified via standard microbiological procedures. Chromogenic media was used to characterize the *Candida* species. The susceptibility of the isolates to the antifungal agents; caspofungin, amphotericin, itraconazole, and *flu*conazole was determined with the E-test.

**Statistical methods:** The data were analysed with Statistical Package for the Social Science SPSS; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows. Comparisons between the study groups were performed using the Chi square ($\chi^2$) test. *p*-values less than 0.05 were considered significant.

**Results:** Candidaemia accounted for 17.3% of all BSIs. *C. albicans* and non-*C. albicans* species accounted for 36% and 64% of the cases of candidaemia, respectively. Caspofungin, amphotericin, itraconazole, and fluconazole antifungals had activities of 99%, 97%, 73% and 64%, respectively. In total, 64% of patients with candaemia died.

**Conclusion:** The prevalence of candidaemia was high, the fatality rate was alarming and non-*C. albicans* species were predominant. Fluconazole was the least effective of the tested antifungal agents owing to the high level of resistance.

**Keywords:** candidaemia, chromogenic agar, antifungal

**Introduction**

Invasive candidiasis is a life-threatening condition that endangers critically ill patients and is associated with a high fatality rate. The mortality rate is unacceptably high, ranging from 29% to 76%.¹ Neonates, elderly patients and those admitted to intensive care units (ICUs) are at greater risk of death than other categories of patients.² Candidaemia is defined as the presence of *Candida* species in the blood determined by at least one positive blood culture in patients with fever and signs of a blood stream infection (BSI).³

Reports of *Candida* BSIs have significantly increased worldwide over the past 20 years. *Candida* BSIs are the fourth most common type of nosocomial BSIs in the USA and they are the sixth most common in Europe.¹,⁴
The World Health Organization (WHO) and the Joint United Nations Program on HIV/AIDS (UNAIDS) reported that in 2011, there were 4,127 cases of candidaemia in the total population of 82,500,000. Immunosuppression, prolonged antibiotic intake, inserted devices, extreme age and ICU admission are all predictive risk factors for invasive candidiasis.

Several studies have reported a change in the type of Candida isolated from blood, with an increasing prevalence of non-C. albicans species. C. tropicalis and C. krusei are commonly observed in leukaemic and neutropenic patients. C. parapsilosis causes 30% of candidaemia cases among new-borns and 10–15% of cases among adults. The emergence of antifungal resistance among Candida species is considered a leading cause of therapeutic failure and the high mortality rate. The present work aimed to calculate the prevalence of candidaemia among pediatric patients, identify the risk factors, characterize the involved species and determine the susceptibility of the isolated strains to antifungal agents, specifically caspofungin, amphotericin B, itraconazole and fluconazole.

Methodology
This study was conducted with positive blood cultures from children suspected of having BSIs in tertiary pediatric hospitals of Cairo University -2017.

Clinical data
The clinical characteristics of the patients with blood cultures positive for Candida were collected including; the hospital site, history of previous administration of antibiotics, associated indwelling devices, factors affecting immunosuppression and 30-day mortality after the diagnosis of Candida BSI. The clinical data were retrieved from the electronic medical records and the associated request form of routine patients’ samples delivered to the laboratory. A written informed consent was obtained by the parents or legal guardians of the patients, and the study was conducted in accordance with the Declaration of Helsinki. The study was reviewed by the Research Ethics Committee (REC) of the Clinical Pathology department at the Faculty of Medicine, Cairo University for all the required ethical statements and was approved with an ID code: I-201008.

Growth detection and species identification
The blood samples were delivered to the laboratory in pediatric blood culture bottles and microbial growth was detected by measuring the signal production with an automated Bact/Alert system (Biormerieux, Craponne, France).

Subculturing of the positive blood cultures was performed on blood, chocolate and MacConkey agar (Oxoid, England) to isolate bacteria and on Sabouraud dextrose medium (BioMérieux, France, REF 43 651) to isolate fungi. The primary differentiation of the isolated Candida species into C. albicans and non-C. albicans species was determined by germ tube test. Further characterization of the Candida species was performed by subculturing on chromogenic Candida agar, which discriminates among different Candida species by color (Oxoid, England, REF: CM1002B). All Candida isolates were stored in glycerol broth at –80 °C.

Antifungal susceptibility testing
Candida isolates were tested for their susceptibility to 4 antifungals; namely, itraconazole, fluconazole, amphotericin B and caspofungin; through the detection of the minimal inhibitory concentrations (MICs) with E-test strips (bioMérieux) and GM-MH agar (Mueller-Hinton agar containing 2% glucose and methylene blue 5 microg/mL). As reported by Lee et al, 2009, the results of the E-test with the GM-MH agar plate are strongly correlated with the results of the antifungal macrodilution susceptibility test. The MICs for the antifungals were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI M27-S4) CLSI, 2012. According to CLSI M27-S4, the sensitive and resistant MICs for C. albicans and C. tropicalis are (≤0.5) µg/ml for fluconazole, (≤0.125 and ≥0.5) µg/ml for itraconazole and (≤0.25 and ≥1) µg/ml for caspofungin. For C. krusei, sensitive and resistant MICs are (≤0.125 and ≥0.5) µg/ml for itraconazole and (≤0.25 and ≥1) µg/ml for caspofungin. The European Committee on Antimicrobial susceptibility testing (EUCAST) guidelines were followed for amphotericin B; the MICs for which have not been defined by the CLSI.

Quality control with reference strains
The reference strains C. albicans ATCC 90028, C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 were used to ensure the quality of antifungal susceptibility tests.

Statistical methods
Data were statistically analysed with Statistical Package for the Social Science (SPSS; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows. Comparisons
between the study groups were made with the Chi square ($\chi^2$) test. $p$-values less than 0.05 were considered significant.

**Results**

Among the 1934 pediatric blood cultures sent to the microbiology laboratory in 2017, 578 (29.8%) were positive for different microorganisms; with 100/578 (17.3%) positive for *Candida*.

A history of previous antibiotic intake for >2 weeks was observed in 75% (75/100) of candidaemia cases. The antibiotics are listed in Figure 1. Immunosuppression was detected in 35 cases in the form of neutropenia (18), steroid intake (10) and both neutropenia and steroid intake (7). The isolated *Candida* species are shown in Figure 2; these isolates were from ICUs and wards in 59% and 41% of the cases, respectively, as shown in Table 1.

The ages of the enrolled patients with candidaemia ranged from birth to 12 years, and they were categorized into the following age groups: 0–28 days (35), >28 days–2 years (41), >2–6 years (22) and >6–12 years (2).

The MICs of amphotericin B for *C. albicans* ATCC 90028 the MICs ranged from 0.125 to 0.5 $\mu$g/mL, and from 0.5 to 1 $\mu$g/mL, respectively; for *C. albicans* ATCC 22019 ranged from 1 to 4 $\mu$g/mL, from 0.12 to 0.5 $\mu$g/mL, and from 0.5 to 1 $\mu$g/mL, respectively; and for *C. krusei* ATCC 6258 the MICs ranged from 0.125 to 0.5 $\mu$g/mL, from 0.064 to 0.25 $\mu$g/mL, and from 0.125 to 0.5 $\mu$g/mL, respectively and for *C. krusei* ATCC 2019 ranged from 1 to 4 $\mu$g/mL, from 0.12 to 0.5 $\mu$g/mL, and from 1 to 4 $\mu$g/mL, respectively; which were all meeting the expected ranges according to the required guidelines by the Clinical and Laboratory Standards Institute.

The descriptive analysis of the MICs is shown in Table 4, with the lowest MIC values were recorded for itraconazole with *C. krusei* with a susceptible range of (0.0–0.09); for *C. albicans* with amphotericin, with a susceptible range of (0.0–0.019); and *C. tropicalis* and other non-*C. albicans* species with caspofungin, with susceptible ranges of (0.01–0.05) and (0.01–0.8), respectively.

After excluding the 14 intrinsically resistant *C. krusei* isolates, fluconazole resistance was recorded in 41.8% (36/86) of the *Candida* isolates; with resistance found in 52.8% and 47.2% of isolates from patients in ICUs and in wards, respectively. Fluconazole resistant *C. albicans* and non-*C. albicans* species accounted for 38.9% and 44% of the total, respectively. As shown in Table 5, devices were found in 88.9% of patients with fluconazole-resistant isolates. Previous fluconazole intake was present in 19.4% (7/36) of fluconazole-resistant cases. In total, 64% (64/100) of patients diagnosed with *Candida* BSI died within 30 days; the descriptive analysis is shown in Table 6. Fluconazole resistance was detected in 34.4% of the deceased patients with *Candida* BSI.

**Discussion**

*Candida* BSIs pose a serious threat, especially to vulnerable patients. In the present study, candidaemia accounted for 100 of the 578 confirmed BSIs with a prevalence of 17.3%. Other studies in Egypt reported candidaemia prevalences of 16% and 19% among pediatric ICU patients with BSIs. A higher prevalence of candidaemia (38%)
was reported in another study conducted with a different study populations of adult patients in internal medicine wards.\(^{17}\)

The results of the present study agreed with those of another Egyptian study, which reported a predominance of non-\(C.\) \(albicans\) species (60\% non-\(C.\) \(albicans\) versus 40\% \(C.\) \(albicans\)).\(^{15}\) This finding was consistent with the results of a study that reported \(C.\) \(albicans\) and non-\(C.\) \(albicans\) BSIs in the neonatal ICU of Child Healthcare, with prevalences of 43.5\% vs 56.5\%, respectively.\(^{18}\) Several studies also reported this pattern in contrast to the results of older published.\(^{6,16,19,20}\)

Another study conducted in Egypt also found that \(C.\) \(tropicalis\) was the second common non-\(C.\) \(albicans\)
species isolated with a prevalence of 17%; the prevalence rates of *C. tropicalis* in other studies were 14.8% and 9.6%. However, those studies reported *C. parapsilosis* as the most common non-*C. albicans* species isolated, while *C. krusei* was the most common species in the present study.

In the present study, candidaemia was most commonly identified in patients in the ICU (59%) and in neonates (35%), which was consistent with the findings of another study. Other studies found fewer patients with candidaemia in ICUs which might be due to more strict adherence to infection control measures.

### Table 3 Results of antifungal susceptibility testing among blood stream isolated Candida

| Candida species | Fluconazole (n=36) | Amphotericin (n=34) | Itraconazole (n=22) | Caspofungin (n=35) |
|----------------|-------------------|-------------------|-------------------|-------------------|
|                | No. | R | S | No. | R | S | No. | R | S |
| *C. albicans*  | 22  | 14 | 34 | 2  | 14 | 35 | 1  |     |     |
|                | % 61.1 | 38.9 | 94.4 | 5.6 | 61.1 | 38.9 | 97.2 | 2.8 |     |
| Non-*C. albicans* (n=64) Total | 28 | 22 | 63 | 1 | 51 | 13 | 64 | 0 |     |
|                | % 56** | 44** | 98.4 | 1.5 | 79.6 | 20.3 | 100 | 0 |     |
| *C. tropicalis* (n=11) | 6 | 5 | 11 | 0 | 9 | 2 | 11 | 0 |     |
|                | % 54.5 | 45.5 | 100.0 | 0.0 | 81.8 | 18.2 | 100.0 | 0.0 |     |
| *C. krusei* (n=14) | - | - | 14 | 0 | 8 | 6 | 14 | 0 |     |
|                | % - | - | 100.0 | 0.0 | 57.1 | 42.9 | 100.0 | 0.0 |     |
| Other species (n=39) | 22 | 17 | 38 | 1 | 34 | 5 | 39 | 0 |     |
|                | % 56.4 | 43.5 | 97.4 | 2.6 | 87.2 | 12.8 | 100.0 | 0.0 |     |

Notes: *C. krusei is intrinsically resistant; **Fluconazole resistance was calculated out of 50 non-*C. albicans*, after exclusion of 14 intrinsically resistant *C. Krusei*.

### Table 4 The descriptive analysis of susceptible MIC values to antifungals

| Candida species | Antifungal agents | MIC values (μg ml⁻¹) |
|----------------|-------------------|---------------------|
|                | Range             | Mean ± SD.          | Median |
| *C. albicans*  | Fluconazole (n=22)| 0.02–1.50           | 0.83±0.65 | 1.0 |
|                | 0.00–0.19         | 0.05±0.04           | 0.03 |
|                | 0.00–0.50         | 0.07±0.10           | 0.05 |
|                | 0.00–0.44         | 0.05±0.08           | 0.02 |
|                | Amphotericin (n=34)| 0.01–0.32           | 0.10±0.11 | 0.05 |
|                | Itraconazole (n=22)| 0.02–0.38           | 0.08±0.11 | 0.04 |
|                | Caspofungin (n=35)| 0.01–0.05           | 0.02±0.01 | 0.01 |
| *C. tropicalis*| Fluconazole (n=11)| 0.16–1.50           | 0.86±0.54 | 0.75 |
|                | Amphotericin (n=11)| 0.01–0.32           | 0.10±0.11 | 0.05 |
|                | Itraconazole (n=9)| 0.02–0.38           | 0.08±0.11 | 0.04 |
|                | Caspofungin (n=11)| 0.01–0.05           | 0.02±0.01 | 0.01 |
| *C. krusei*    | Amphotericin (n=14)| 0.02–0.13           | 0.06±0.03 | 0.06 |
|                | Itraconazole (n=8)| 0.00–0.09           | 0.04±0.03 | 0.04 |
|                | Caspofungin (n=14)| 0.01–0.09           | 0.03±0.02 | 0.02 |
| Other species  | Fluconazole (n=22)| 0.0–1.50            | 0.72±0.61 | 1.0 |
|                | Amphotericin (n=38)| 0.0–1.0             | 0.07±0.16 | 0.05 |
|                | Itraconazole (n=34)| 0.01–0.50           | 0.07±0.11 | 0.03 |
|                | Caspofungin (n=39)| 0.01–0.80           | 0.05±0.13 | 0.02 |

Note: The MICs for fluconazole, itraconazole and amphotericin B for *C. parapsilosis* ATCC 22,019 ranged from 1 to 4 μg/mL, from 0.12 to 0.5 μg/mL, and from 0.5 to 1 μg/mL, respectively; for *C. albicans* ATCC 90,028 the MICs ranged from 0.125 to 0.5 μg/mL, from 0.064 to 0.25 μg/mL, and from 0.125 to 0.5 μg/mL, respectively and for *C. krusei* ATCC 6258 the MICs ranged from 16 to 128 μg/mL, from 0.25 to 1 μg/mL, and from 1 to 4 μg/mL, respectively, which were all meeting the expected ranges according to the required guidelines by the Clinical and Laboratory Standards Institute.
The findings of the present study were compatible with those of other studies with regard to the risk factors for candidaemia; the most important risk factor was previous exposure to antibiotics for >14 days, followed by the presence of a central venous line, and *C. albicans* was more commonly isolated than non-*C. albicans* species.

With regards to antifungal resistance, 3% of the isolates were resistant to amphotericin; which was consistent with the results of another study (6.9%). This resistance was due to prior extensive use of amphotericin B in immunocompromised patients, unlike in other studies that reported no amphotericin B resistance.\textsuperscript{23–25} The present study showed that 27% of the isolates, mostly *C. albicans* and not *C. tropicalis* were resistant to itraconazole resistance; which agreed with some of the previous studies.\textsuperscript{24–25} Caspofungin resistance rates remained low; the present study found that 1% of the isolates were resistant to caspofungin.\textsuperscript{26}

The rate of fluconazole resistance was 41.8%, and more non-*C. albicans* species were resistant than *C. albicans* species (44% versus 38.9%). A higher rate of fluconazole resistance was found in *C. tropicalis* than in *C. albicans*, which was similar to the results of one study (7.2% versus 1.3%), while the opposite trend was observed in another study.\textsuperscript{7,22}

Generally, ICUs are considered epicenters of antimicrobial resistance.\textsuperscript{18,20} In the present study, the majority of fluconazole-resistant isolates (52.8%) were recovered from patients in ICUs, which agreed with the findings of another study, which recovered 94% of the isolates from ICUs.\textsuperscript{27}

The majority of enrolled cases (64%) died within experienced 30 days of diagnosis, of whom 34.4% were resistant to fluconazole; these findings agreed with those of another study that found resistance in 41.1% of deceased cases.\textsuperscript{28} Several studies reported mortality rates of 51.2% and 42.4% among patients with candidaemia.\textsuperscript{16,21} As in other studies, we observed higher mortality rates in patients infected with non-*C. albicans* species than in patients infected with *C. albicans* (65.6% versus 34.4%, respectively).\textsuperscript{20,23}

### Table 5  The association of Fluconazole resistance with indwelling devices

| Device                      | Fluconazole          | p-value |
|-----------------------------|----------------------|---------|
|                             | S (n=64) | R (n=36) |         |
| No.                         | %        | No.      | %        |
| No associated devices       | 13       | 20.3     | 4        | 11.1     | 0.240 |
| Associated devices          | 51       | 79.7     | 32       | 88.9     |       |
| Types                       |          |          |          |          |       |
| CVL                         | 36       | 56.3     | 28       | 77.8     | 0.031* |
| Urinary catheter            | 19       | 29.7     | 13       | 36.1     | 0.509 |
| Ventilator                  | 30       | 46.9     | 19       | 52.8     | 0.571 |
| Ryle                        | 30       | 46.9     | 21       | 58.3     | 0.271 |
| Prosthetic valve            | 4        | 6.3      | 4        | 11.1     | 0.6<sup>Fe</sup> |

Notes: \textsuperscript{16}p. p-value for Fisher Exact for Chi square test for comparing between the two groups. \textsuperscript{*}Statistically significant at p≤0.05.

### Table 6  Descriptive analysis of developed mortality among candidaemia cases

| Mortality among candidaemia (n=64) | No. | %     |
|-----------------------------------|-----|-------|
| Age (years)                       |     |       |
| 0–28 days                         | 21  | 32.8  |
| >28 days–2 years                  | 31  | 48.4  |
| >2–6 years                        | 11  | 17.2  |
| >6–12 years                       | 1   | 1.6   |
| Fluconazole                       |     |       |
| Sensitive                         | 42  | 65.6  |
| Resistant                         | 22  | 34.4  |
| C. albicans                       | 22  | 34.4  |
| Non-C. albicans                   |     |       |
| C. tropicalis                     | 6   | 9.4   |
| C. krusei                         | 8   | 12.5  |
| Other species                     | 28  | 43.8  |
| Total                             | 42  | 65.6  |

The findings of the present study were compatible with those of other studies with regard to the risk factors for candidaemia; the most important risk factor was previous exposure to antibiotics for >14 days, followed by the presence of a central venous line, and *C. albicans* was more commonly isolated than non- *C. albicans* species.\textsuperscript{20,23}

With regards to antifungal resistance, 3% of the isolates were resistant to amphotericin; which was consistent with the results of another study (6.9%). This resistance was due to prior extensive use of amphotericin B in immunocompromised patients, unlike in other studies that reported no amphotericin B resistance.\textsuperscript{23–25} The present study showed that 27% of the isolates, mostly *C. albicans* and not *C. tropicalis* were resistant to itraconazole resistance; which agreed with some of the previous studies.\textsuperscript{24–25} Caspofungin resistance rates remained low; the present study found that 1% of the isolates were resistant to caspofungin.\textsuperscript{26}

The rate of fluconazole resistance was 41.8%, and more non-*C. albicans* species were resistant than *C. albicans* species (44% versus 38.9%). A higher rate of fluconazole resistance was found in *C. tropicalis* than in *C. albicans*, which was similar to the results of one study (7.2% versus 1.3%), while the opposite trend was observed in another study.\textsuperscript{7,22}

Generally, ICUs are considered epicenters of antimicrobial resistance.\textsuperscript{18,20} In the present study, the majority of fluconazole-resistant isolates (52.8%) were recovered from patients in ICUs, which agreed with the findings of another study, which recovered 94% of the isolates from ICUs.\textsuperscript{27}

The majority of enrolled cases (64%) died within experienced 30 days of diagnosis, of whom 34.4% were resistant to fluconazole; these findings agreed with those of another study that found resistance in 41.1% of deceased cases.\textsuperscript{28} Several studies reported mortality rates of 51.2% and 42.4% among patients with candidaemia.\textsuperscript{16,21} As in other studies, we observed higher mortality rates in patients infected with non- *C. albicans* species than in patients infected with *C. albicans* (65.6% versus 34.4%, respectively).\textsuperscript{20,23}

**Conclusion**

In the present study, candidaemia accounted for 17.3% of all BSIs among pediatric patients, with a predominance of
non-\textit{C. albicans} species. Caspofungin had the highest antifungal activity, while fluconazole had the least. The early diagnosis of \textit{Candida} BSI and its resistance profile are essential to improve outcomes, especially in critically ill neonates and children of preschool age.

\section*{Limitations}

The lack of availability of advanced molecular techniques in the present study limited the ability to identify the genetic basis of the antifungal resistance and the determination of the degree of genetic relatedness of the isolated \textit{Candida} species. CHROM agar was challenged by lacking ability to discriminate some non-\textit{C. albicans} species, which all give similar beige/brown/yellow colors, due to the mixture of natural pigmentation and some alkaline phosphatase enzyme activity.

\section*{Disclosure}

The authors report no conflicts of interest in this work.

\section*{References}

1. Diekema D, Arbelleve S, Boyken L, Kroeger J, Pfaffer M. The changing epidemiology of healthcare-associated candidemia over three decades. \textit{Diag Microbiol Infect Dis.} 2012;73(1):45–48. doi:10.1016/j.diagmicrobio.2012.02.001

2. Bajwa S, Kulshrestha A. Fungal infections in intensive care unit: challenges in diagnosis and management. \textit{Ann Med Health Sci Res.} 2013;3:238. doi:10.4103/2141-9248.113669

3. Hesstvedt L, Gaustad P, Andersen CT, et al. Twenty-two years of candidemia surveillance: results from a Norwegian national study. \textit{Clin Microbiol Infect.} 2015;21:938–945. doi:10.1016/j.cmi.2015.06.008

4. Ericson EL, Klingspor L, Ullberg M, et al. Clinical comparison of the Bactec Mycosis IC/F, BacT/Alert FA, and BacT/Alert FN blood culture vials for the detection of candidemia. \textit{Diag Microbiol Infect Dis.} 2012;73:153–156. doi:10.1016/j.diagmicrobio.2012.02.020

5. Zaki SM, Denning DW. Serious fungal infections in Egypt. \textit{Eur J Clin Microbiol Infect Dis.} 2017;36(6):971–974. doi:10.1007/s10096-017-2929-4

6. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans \textit{Candida} species versus \textit{Candida albicans} in the intensive care unit. \textit{Clin Infect Dis.} 2008;46:1206–1213. doi:10.1086/529435

7. Lyon GM, Karatela S, Sunay S. Antifungal susceptibility testing of \textit{Candida} isolates from the candidemia surveillance study. \textit{J Clin Microbiol.} 2010;48(4):1270–1275. doi:10.1128/JCM.02363-09

8. Pfaffer MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent problem. \textit{Clin Microbiol Rev.} 2007;20(1):133–163. doi:10.1128/CMR.00029-06

9. BioMérieux product list. 2012. Available from: www.bioMérieux. com. Accessed July 2016.

10. Oxoid product list. 2012. Available from: www.oxoid.com. Accessed July 2016.

11. Cheesbrough M. Microbiological tests. In: Cheesbrough M, editor. \textit{District Laboratory Practice in Tropical Countries}. 2nd ed. 2009. Cambridge University Press: Part II, Chapter (7). 1–266.

12. Lee SC, LO HJ, Fung CP, Lee N, See LC. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of \textit{Candida} species to voriconazole and fluconazole. \textit{J Microbiol Immunol Infect.} 2009;42(2):148–153.

13. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. (Document M27-S4).

14. Alastruy-Izquierdo A, Melhem MSC, Bonifieli LX, Rodriguez-Tudela JL. Susceptibility test for fungi: clinical and laboratory correlations in medical mycology. \textit{Rev Inst Med Trop Sao Paulo.} 2015;57(19):57–64. doi:10.1590/S0036-4665201500000011

15. Fu J, Ding Y, Wei B, et al. Epidemiology of \textit{Candida albicans} and non-\textit{C. albicans} of neonatal candidemia at a tertiary care hospital in western China Journal List. \textit{BMC Infect Dis.} 2017;17(1):329. doi:10.1186/s12879-017-2757-2

16. Hegazi M, Abdellaker A, Zaki M, El-Deek B. Characteristics and risk factors of candidemia in pediatric intensive care unit of a tertiary care children’s hospital in Egypt. \textit{J Infect Dev Ctries.} 2014;8(5):624–634. doi:10.3855/jidc.4186

17. Gupta P, Prateek S, Chatterjee B, Kotwal A, Singh AK, Mittal G. Prevalence of candidaemia in ICU in a tertiary care hospital in North India. \textit{Int J Curr Microbiol Sci.} 2015;4(6):566–575.

18. Frainow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. \textit{Crit Care Clin.} 2011;27(1):163–205. doi:10.1016/j.ccc.2010.11.002

19. Dutta A, Palazzi DL. \textit{Candida non-albicans} versus \textit{Candida albicans} fungemia in the non-neonatal pediatric population. \textit{Pediatr Infect Dis J.} 2011;30(8):664–668. doi:10.1097/INF.0b013e3182121dad0f

20. Rajendran RL, Sherry CJ, Nile A, et al. Biofilm formation is a risk factor for mortality in patients with \textit{Candida albicans} bloodstream infection—scotland, 2012–2013. \textit{Clin Microbiol Infect.} 2016;22(1):87–93. doi:10.1016/j.cmi.2015.09.018

21. Tumarello M, Fiori B, Trecarichi EM, et al. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. \textit{PLoS ONE.} 2012;7(3):e33705. doi:10.1371/journal. pone.0033705

22. Furlaneto MC, Rota JF, Quesada RM, et al. Species distribution and in vitro fluconazole susceptibility of clinical \textit{Candida} isolates in a Brazilian tertiary-care hospital over a 3-year period. \textit{Rev Soc Bras Med Trop.} 2011;44(5):595–599.

23. Caggiano G, Coretti C, Bartolomeo N, Lovero G, De Giglio O, Montagna MT. \textit{Candida} bloodstream infections in Italy: changing epidemiology during 16 years of surveillance. \textit{Biomed Res Int.} 2015;2015:256580. doi:10.1155/2015/256580

24. Capoor MR, Nair D, Deb M, Verma PK, Srivastava L, Aggarwal P. Emergence of non-\textit{albicans Candida} species and antifungal resistance in tertiary care hospital. \textit{Jpn J Infect Dis.} 2005;58(6):344–348.

25. Mota AJ, Grazziella N, Back-Brito GN, Nobrega FG. Molecular identification of \textit{Pichia guilliermondii}, \textit{Debaryomyces hansenii} and \textit{Candida palmioleophila}. \textit{Genet Mol Biol.} 2012;35:122–125.

26. Shields RK, Nguyen MH, Clancy CJ. Clinical perspectives on echinocandins resistance among \textit{Candida} species. \textit{Curr Opin Infect Dis.} 2015;28(6):514–522. doi:10.1097/QCO.0000000000000215

27. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrales E, et al. Risk factors for fluconazole-resistant candidemia. \textit{Antimicrob Agents Chemother.} 2010;54:3149–3154. doi:10.1128/AAC.00479-10

28. Liao X, Qiu H, Li R, et al. Risk factors of fluconazole-resistant invasive candidiasis in intensive care unit patients. \textit{J Crit Care.} 2015;30(4):862e1–862e5.
